Morgan Stanley Nektar Therapeutics Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Nektar Therapeutics stock. As of the latest transaction made, Morgan Stanley holds 584,117 shares of NKTR stock, worth $13.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

584,117

Previous 802,342 27.2%

Holding current value

$13.8 Million

Previous $746,000 46.78%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.66 - $1.19 $144,028 - $259,687	-218,225 Reduced 27.2%	584,117 $397,000
Q4 2024 Feb 14, 2025	BUY	$0.9 - $1.45 $50,605 - $81,530	56,228 Added 7.54%	802,342 $746,000
Q3 2024 May 14, 2025	SELL	$1.11 - $1.48 $806,433 - $1.08 Million	-726,517 Reduced 49.33%	746,114 $969,000
Q3 2024 Nov 14, 2024	SELL	$1.11 - $1.48 $806,433 - $1.08 Million	-726,517 Reduced 49.33%	746,114 $969,000
Q2 2024 May 14, 2025	BUY	$0.9 - $1.83 $603,260 - $1.23 Million	670,289 Added 83.54%	1,472,631 $1.83 Million
Q2 2024 Oct 17, 2024	BUY	$0.9 - $1.83 $1.17 Million - $2.39 Million	1,303,831 Added 772.41%	1,472,631 $1.83 Million
Q2 2024 Aug 14, 2024	BUY	$0.9 - $1.83 $1.17 Million - $2.39 Million	1,303,831 Added 772.41%	1,472,631 $1.83 Million
Q1 2024 Oct 17, 2024	SELL	$0.49 - $0.96 $638,877 - $1.25 Million	-1,303,831 Reduced 88.54%	168,800 $156,000
Q1 2024 Aug 16, 2024	SELL	$0.49 - $0.96 $185,684 - $363,790	-378,948 Reduced 69.18%	168,800 $156,000
Q1 2024 May 15, 2024	SELL	$0.49 - $0.96 $185,684 - $363,790	-378,948 Reduced 69.18%	168,800 $156,000
Q4 2023 Aug 16, 2024	SELL	$0.42 - $0.57 $388,450 - $527,183	-924,883 Reduced 62.8%	547,748 $306,000
Q4 2023 Feb 13, 2024	SELL	$0.42 - $0.57 $127,000 - $172,357	-302,382 Reduced 35.57%	547,748 $306,000
Q3 2023 Nov 15, 2023	SELL	$0.51 - $1.05 $368,976 - $759,658	-723,484 Reduced 45.98%	850,130 $510,000
Q2 2023 Aug 14, 2023	SELL	$0.53 - $1.03 $145,119 - $282,025	-273,811 Reduced 14.82%	1,573,614 $912,000
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $130,679 - $643,185	204,186 Added 12.43%	1,847,425 $1.29 Million
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $1.34 Million - $2.82 Million	-659,615 Reduced 28.64%	1,643,239 $3.71 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $38,279 - $64,722	12,592 Added 0.55%	2,302,854 $7.37 Million
Q2 2022 Oct 27, 2022	BUY	$3.17 - $6.17 $1.93 Million - $3.75 Million	607,428 Added 36.1%	2,290,262 $8.7 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $1.93 Million - $3.75 Million	607,428 Added 36.1%	2,290,262 $8.7 Million
Q1 2022 Oct 27, 2022	SELL	$4.16 - $13.72 $2.53 Million - $8.33 Million	-607,428 Reduced 26.52%	1,682,834 $9.07 Million
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $759,062 - $2.5 Million	182,467 Added 12.16%	1,682,834 $9.07 Million
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $6.87 Million - $11.7 Million	634,509 Added 73.28%	1,500,367 $20.3 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $11.3 Million - $16.3 Million	865,858 New	865,858 $15.6 Million

Others Institutions Holding NKTR

# of Institutions

Shares Held

16.8M

Call Options Held

17.2K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $4.42B
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account